1. Home
  2. Stocks
  3. Eris Share Price

Eris Lifesciences Share Price

Pharmaceuticals Mid Cap

₹1,311.55 -6 (-0.46%)

05 Nov, 2024 21:52

SIP TrendupStart SIP in ERIS

Start SIP
Performance Financial Technical Events FnO Shareholding Pattern More FAQ’s

Performance

  • Low
  • ₹1,287
  • High
  • ₹1,321
  • 52 Week Low
  • ₹809
  • 52 Week High
  • ₹1,522
  • Open Price₹1,298
  • Previous Close₹1,318
  • Volume50,539

Investment Returns

  • Over 1 Month -2.89%
  • Over 3 Month + 17%
  • Over 6 Month + 50.8%
  • Over 1 Year + 50.23%
SIP Lightning

Smart Investing Starts Here Start SIP with Eris Lifesciences for Steady Growth!

Eris Lifesciences Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 51.2
  • PEG Ratio
  • -5.3
  • Market Cap Cr
  • 17,851
  • P/B Ratio
  • 6.9
  • Average True Range
  • 48.65
  • EPS
  • 21.8
  • Dividend Yield
  • 0
  • MACD Signal
  • -8.43
  • RSI
  • 47.47
  • MFI
  • 25.07

Eris Lifesciences Financial

IndicatorSep 24Jun 24Mar 24Dec 23Sep 23
Net Sales/Income from operations428.75449.17332.25315.96409.71
Total Income From Operations428.75456.69341.30324.41409.71
P/L Before Interest, Excpt. Items & Tax102.2882.9970.6449.78126.47
P/L Before Exceptional Items & Tax46.0226.8241.7534.64119.92
P/L After Tax from Ordinary Activities28.1017.0439.5131.66117.81
Net Profit/Loss For the Period28.1017.0439.5131.66117.81
IndicatorMar 24Mar 23
Revenue From Operations [Gross]1,454.751,307.12
Revenue From Operations [Net]1,454.751,307.12
Total Operating Revenues1,486.711,330.73
Total Revenue1,521.531,347.99
Total Expenses1,192.70911.08
Profit/Loss Before Tax328.83436.91
Profit/Loss For The Period299.71398.01
IndicatorMar 24Mar 23
Net CashFlow - Operating Activity336.29322.33
Net Cash Used In Investing Activity-2,491.89-513.30
Net Cash Used in Finance Activity2,160.06193.75
Net Inc/Dec In Cash And Equivalent4.452.78
Cash And Equivalent End Of Year51.9447.48
IndicatorMar 24Mar 23
Total Share Capital13.6013.60
Total Non-Current Liabilities563.77278.00
Total Current Liabilities2,261.78283.77
Total Capital And Liabilities5,349.572,783.66
Total Non-Current Assets3,473.022,231.58
Total Current Assets1,876.55552.08
Total Assets5,349.572,783.66
Indicator20242023
EBIT Margin (%)25.9834.39
Return On Capital Employed (%)12.5018.30
Return On Equity (%)11.8717.91
Long Term Debt To Equity (%)19.259.42
Book Value/Share (INR)185.55163.39
IndicatorSep 24Jun 24Mar 24Dec 23Sep 23
Net Sales/Income from operations738.95715.59547.27483.48505.30
Total Income From Operations738.95719.72550.93486.30505.30
P/L Before Interest, Excpt. Items & Tax188.58175.69109.68133.99142.53
P/L Before Exceptional Items & Tax129.11115.3276.65115.87126.24
P/L After Tax from Ordinary Activities96.3589.4279.63101.46122.31
Net Profit/Loss For the Period96.3589.4279.63101.46122.31
IndicatorMar 24Mar 23
Revenue From Operations [Gross]1,991.301,661.82
Revenue From Operations [Net]1,991.301,661.82
Total Operating Revenues2,009.141,685.15
Total Revenue2,032.961,696.30
Total Expenses1,601.721,291.66
Profit/Loss Before Tax431.24404.64
Profit/Loss For The Period397.05374.16
IndicatorMar 24Mar 23
Net CashFlow - Operating Activity486.01291.74
Net Cash Used In Investing Activity-1,854.52-982.10
Net Cash Used in Finance Activity1,379.78688.03
Net Inc/Dec In Cash And Equivalent11.265.15
Cash And Equivalent End Of Year94.2556.02
IndicatorMar 24Mar 23
Total Share Capital13.6013.60
Total Non-Current Liabilities1,294.731,003.42
Total Current Liabilities2,532.08443.23
Total Capital And Liabilities7,048.843,667.33
Total Non-Current Assets4,746.772,902.61
Total Current Assets2,302.07764.72
Total Assets7,048.843,667.33
Indicator20242023
EBIT Margin (%)25.6825.56
Return On Capital Employed (%)11.4213.36
Return On Equity (%)15.1517.40
Long Term Debt To Equity (%)25.3029.34
Book Value/Share (INR)190.11163.30

Eris Lifesciences Technicals

EMA & SMA

Current Price
₹1,311.55
-6 (-0.46%)
pointer
  • stock-down_img
  • Bullish Moving Average 7
  • stock-up_img
  • Bearish Moving Average 9
  • 20 Day
  • ₹1,321.73
  • 50 Day
  • ₹1,306.99
  • 100 Day
  • ₹1,230.59
  • 200 Day
  • ₹1,110.98

Resistance and Support

1306.67 Pivot Speed
  • R3 1,360.78
  • R2 1,341.12
  • R1 1,326.33
  • S1 1,291.88
  • S2 1,272.22
  • S3 1,257.43

Is Eris Lifesciences Worth Buying?

BUY SELL HOLD

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Eris Lifesciences Ltd. is a leading Indian pharmaceutical company specializing in chronic and sub-chronic therapies. With 70% in-house manufacturing and a pan-India distribution network, Eris generates 86% of its revenue from chronic care, serving over 500,000 chemists nationwide. Eris Lifesciences has an operating revenue of Rs. 2,495.89 Cr. on a trailing 12-month basis. An annual revenue growth of 20% is outstanding, Pre-tax margin of 21% is great, ROE of 15% is good. The company has a reasonable debt to equity of 25%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and around 26% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 13% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 48 which is a POOR score indicating inconsistency in earnings, a RS Rating of 76 which is FAIR indicating the recent price performance, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 113 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment. Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation. (+)

Eris Lifesciences Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-10-25 Quarterly Results
2024-08-02 Quarterly Results
2024-05-21 Audited Results & Fund Raising
2024-02-13 Quarterly Results
2023-11-08 Quarterly Results
Date Purpose Remarks
2022-08-16 INTERIM Rs.7.35 per share(735%)Interim Dividend
2021-08-06 INTERIM Rs.6.01 per share(601%)Interim Dividend

Eris Lifesciences F&O

Eris Lifesciences Shareholding Pattern

54.87%
17.03%
0.92%
8.01%
0%
10.52%
8.65%
  • NSE Symbol
  • ERIS
  • BSE Symbol
  • 540596
  • Chairperson & Managing Director
  • Mr. Amit Bakshi
  • ISIN
  • INE406M01024

Eris Lifesciences FAQs

Eris Lifesciences share price is ₹1,311 As on 05 November, 2024 | 21:38

The Market Cap of Eris Lifesciences is ₹17851 Cr As on 05 November, 2024 | 21:38

The P/E ratio of Eris Lifesciences is 51.2 As on 05 November, 2024 | 21:38

The PB ratio of Eris Lifesciences is 6.9 As on 05 November, 2024 | 21:38

Q2FY23
Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

The Vigilance Awareness Week for the year 2024 (VAW 2024) would be observed from October 28, 2024 to November 03, 2024
“सत्यनिष्ठा की संस्कृनि सेराष्र की समद्ृधि” “Culture of Integrity for Nation's Prosperity”
e-pledge link (https://pledge.cvc.nic.in/)

5paisa Capital Ltd. CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI-registered Mutual Fund Distributor | AMFI REGN No.: ARN-104096 | Date of initial Registration: 30/07/2015 | Current validity of ARN : 30/07/2027 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

*Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of ₹10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support Desk Helpline: 8976689766

Contact Us

Attention Investors

  • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
  • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
  • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

Email: support@5paisa.com

Support Desk Helpline: 8976689766

©2024, 5paisa Capital Ltd. All Rights Reserved. We are ISO 27001:2013 Certified.